Velusetrag
As of the edition of 20 October 2026, Velusetrag is a small molecule: in active development; acts on HTR4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2012
- Kind
- Small molecule
- Registered trials
- 5, 0 stopped early
- Disease areas
- Digestive system; Immune system; Lungs and airways; Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HTR4 | 5-hydroxytryptamine receptor 4 | Q13639 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 4 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Alfasigma | Lead sponsor of trials | 2006 to now |
| Theravance Biopharma | Lead sponsor of trials | 2012 to now |